Boehringer Ingelheim to Announce Pivotal Phase 3 Hepatitis C Data at the International Liver Congress

The STARTVersoa 1 trial evaluated faldaprevir , an investigational oral protease inhibitor specifically designed to target and inhibit viral replication in the liver, in combination with pegylated interferon and ribavirin .

http://www.drugs.com/clinical_trials/boehringer-ingelheim-announce-pivotal-phase-3-hepatitis-c-data-international-liver-congress-15326.html